Showing results (1111-1120 of 1,274) with videos related to
Sort By:
Pageof 128
British Journal of Haematology|September 4, 2010
Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridizationSunita R Setlur, Chunhwa Ihm, Joelle Tchinda, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 1, 1996
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristicsA Schatzkin, E Lanza, L S Freedman, et al.Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.Neurology|February 12, 2016
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO studyPaul O'Connor, Giancarlo Comi, Mark S Freedman, et al.Leukemia Research|December 5, 2003
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivoJonathan W Friedberg, Danielle A Dong, Sigui Li, et al.The Journal of Biological Chemistry|February 14, 1997
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cellsS N Manié, A R Beck, A Astier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinomaA P Kudelka, D Tresukosol, C L Edwards, et al.British Journal of Haematology|April 7, 2009
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomasJennifer R Brown, Jonathan W Friedberg, Yang Feng, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 31, 2026
Basal phosphorylation of SHIP1 by Lyn suppresses proinflammatory signaling in the absence of a phagocytic synapseS Erandika Senevirathne, William K Kanagy, Charlotte R Hemmila, et al.Journal of Neurology|March 25, 2026
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension studyXavier Montalban, Reinhard Hohlfeld, Carlo Pozzilli, et al.Pageof 128